Dubai-headquartered Kelix Bio, wholly owned by Abu Dhabi’s Mubadala Investment Mubadala, has completed the acquisition of insulin manufacturer DiabTec, a subsidiary of Ras Al Khaimah-headquartered Julphar, for an undisclosed fee.
According to a media release, the deal strengthens Mubadala's portfolio of biologicals, establishes its role in biomanufacturing across the Middle East and North Africe MENA region, and supports its efforts to advance the United Arab Emirates UAE life sciences sector through local manufacturing.
DiabTec's facility includes 20,000-liter drug substance reactors and a separate cartridge fill-finish facility for drug products the facility is built to EUUS FDA standards.
Mubadala...
¬ Haymarket Media Limited. All rights reserved.
